Dyadic International (DYAI) 10-Q2023 Q1 Quarterly report

Filed: 10 May 23, 4:35pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accessible, accumulated, affinity, BARDA, began, Biomedical, bioproduction, bovine, building, bulk, CECL, circulating, Codification, commitment, component, composition, core, CSR, dairy, deficit, developmental, distribute, DNA, dozen, durable, earned, education, endonuclease, entitled, enzyme, ethical, EU, exploit, extensive, facilitate, favorable, FDA, Fermbox, field, final, Flu, forum, fungi, growth, half, highlighted, hosted, identification, intramuscular, intranasal, journal, lieu, LPLV, Marburg, member, modified, newly, nonexclusive, Patient, physicochemical, procured, proposition, prove, range, remote, retrospective, RVFV, sampling, scheduled, science, shorter, side, Southern, spike, standard, strain, Sudan, TBEV, titled, Trademark, transect, UC, unknown, unvested, upcoming, Virovax, virtual, Visit, WNV, workshop, wrong

Removed: acceptable, actively, acute, adequate, allocation, amendment, anticipated, applied, approach, beginning, calculating, capable, combined, companion, comparable, complex, concept, concluding, conducted, constitute, context, controlling, created, creating, criteria, CTA, curb, daily, demonstrated, depend, depression, determinable, discount, doubtful, efficient, element, EUR, evolution, exclusively, exist, extending, flexible, flow, Framework, good, improving, intention, introduced, investee, lack, led, letter, longer, lower, Luina, mAb, methodology, mice, minimum, monitor, mono, move, national, neutralization, neutralizing, noted, Novovet, offered, opportunity, optional, outbreak, perform, prerequisite, profitable, proof, Pty, readily, recession, regional, rely, removing, represented, reservation, reserve, respiratory, risky, RSA, safe, SAHPRA, secure, SFA, Shareholder, simplify, Simplifying, Spanish, specifically, speed, spend, spread, stage, standalone, steering, subordinated, subsided, syndrome, travel, treated, unavailability, USD, VLP, vlpbio, workforce, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated DYAI transcripts

DYAI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Dyadic International, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark A. Emalfarb, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	May 10, 2023
By:	/s/ Mark A. Emalfarb

Name:	Mark A. Emalfarb
Title:	Chief Executive Officer